Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
Want to see SE:XBRANE full AI Analyst Report?
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr38.03
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr240.05M
Enterprise Valuekr129.53M
Total Cash (Recent Filing)kr66.75M
Total Debt (Recent Filing)kr56.88M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Jul 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.99
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr183.00M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageCurrent low reported debt-to-equity (~0.10x) gives Xbrane structural financial flexibility uncommon for small biotechs. A conservative leverage profile reduces near-term default and refinancing risk, supporting continued R&D and partnering activity over the next 2–6 months.
In-house Biologics Development & ManufacturingOwning process development and clinical manufacturing capabilities is a durable strategic asset for a biosimilar developer. It enables fee-based revenue, accelerates internal program timelines, and makes Xbrane a more attractive partner, diversifying cash sources beyond milestone-dependent licensing.
Positive Gross Margin And Improved Reported EarningsA ~46% gross margin indicates structurally defensible unit economics on product costs, and recent reported net income/ROE improvement shows progress toward profitability. If sustained, these trends support longer-term margin recovery and reduce dependence on external financing.
Bears Say
Persistent Negative Cash FlowMaterial negative operating and free cash flow implies ongoing cash burn and reliance on external funding. Over a multi-month horizon this increases dilution or covenant/financing risk, and constrains the firm's ability to scale manufacturing or fund late-stage clinical work without new capital.
Sharp Revenue Decline And Top-line VolatilityA roughly 50% TTM revenue drop and historical top-line swings reduce predictability of future cash generation and weaken negotiating leverage with partners. Structural revenue volatility makes planning manufacturing capacity and financing more difficult and raises execution risk.
Core Operating Losses And Earnings Quality ConcernsPersistent negative EBIT despite gross margin strength suggests operating costs or non-recurring items drive losses. Reliance on non-operational items to show net income undermines earnings quality and signals that core operations are not yet self-sustaining, a multimonth structural weakness.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr38.03 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr240.05M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Jul 17, 2026 which is in 56 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on May 05, 2026. The company reported -kr0.634 earnings per share for the quarter, missing the consensus estimate of -kr0.52 by -kr0.114.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr0.634 in its last earnings report, missing expectations of -kr0.52. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---